Pretium Resources (PVG) Skyrockets on Bulk Sample Results, Biogen

New Post Public Reply Private Reply Replies (0) Message Board
karnacua2

http://pennyomega.com/img/pvg.jpg

Shares of Pretium Resources Inc. (PVG) jumped $2.34 (or +79.86%) to $5.27 on Friday's market activity, after the company reported that 4,215 ounces of gold have been produced from 8,090 dry tonnes of excavated material from the Valley of the Kings Bulk Sample Program. Approximately 1,815 wet tonnes remain to be processed.

The results to date surpass the target of 4,000 ounces of gold projected to be produced from the entire 10,000 tonnes of material excavated for the Program. Processing is continuing on track and is expected to be completed by the first week of December (after a week-long mill shutdown for the U.S. Thanksgiving holiday).

Shipment and sale of the gravity concentrate has commenced, with shipment of the flotation concentrate to commence on completion of processing. The final amount of gold production will be announced at the end of processing and assaying which is expected by mid-December.

PVG was also upgraded from Market Perform to Outperform by brokerage firm BMO Capital Markets

http://pennyomega.com/img/pvg_chart.png

PVG is creating value through gold at its high-grade gold Brucejack Project, located in northern British Columbia. Processing of the 10,000-tonne Valley of the Kings bulk sample is expected to be completed this quarter. Permitting of a high-grade underground gold mine at Brucejack is underway, with commercial production targeted to commence in 2016.

More about Pretium Resources Inc. (PVG) at www.pretivm.com

**

http://pennyomega.com/img/crwe_logo.jpg

Industry analyst firm Forrester estimates the B2B e-commerce market is expected to reach $559 billion by the end of 2013.

According to comScore, 188.7 million people in the US watched 46 billion online content videos in September 2013. The average American spent more than 20 hours watching online video.

Looking to deliver value for its stockholders in both the near and long term, Crown Equity Holdings Inc. (CRWE) is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online video-sharing and online b2b markets, with its Division CRWETube ( www.crwetube.com ) and its iB2B Global project, respectively.

http://pennyomega.com/img/crwenov22.png

As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

http://pennyomega.com/img/biib.jpg

The price of Biogen Idec Inc. (BIIB) stock soared after the company reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has determined that dimethyl fumarate in TECFIDERA qualifies as a new active substance. This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union (EU).

The new active substance determination follows a positive opinion by the CHMP in March 2013 recommending marketing authorization in the EU for TECFIDERA as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis

The CHMP’s determination will now be referred to the European Commission, which grants marketing authorization for medicines in the EU.

TECFIDERA, an oral therapy for relapsing forms of multiple sclerosis, is currently approved in the United States, Canada and Australia, and is under review by regulatory authorities in the European Union.

If approved, TECFIDERA will mark the fourth therapy that BIIB offers to people living with multiple sclerosis in the European Union.

BIIB closed at $285.62, up $33.19 (or +13.15%) on Friday's trading session

http://pennyomega.com/img/biib_chart.png

Through cutting-edge science and medicine, BIIB discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders.

More about Biogen Idec Inc. (BIIB) at www.biogenidec.com .

**

http://pennyomega.com/img/xec.jpg

Cimarex Energy Co. (XEC) stock was upgraded from Hold to Buy and price target of $120 by brokerage firm Stifel. XEC shares climbed $1.86 (or +1.87%), closing at $101.24 on Friday.

XEC recently reported its financial results. For the third quarter 2013, XEC posted net income of $138.4 million, or $1.59 per diluted share, compared to $84.3 million, or $0.97 per diluted share in the same period the prior year.

According to its business outlook, XEC estimates fourth quarter 2013 total company volumes to average 714-734 MMcfe per day. As a result, 2013 total company volumes are now projected to average 695-700 MMcfe/d, 11 to 12%v growth over 2012 with oil volumes projected to grow 18%. Adjusted for property sales in 2012, production is expected to grow 14%.

http://pennyomega.com/img/xec_chart.png

XEC is an independent oil and gas exploration and production company with principal operations in the Mid-Continent and Permian Basin areas of the U.S.

More about Cimarex Energy Co. (XEC) at www.cimarex.com .

**

Read Full Disclaimer at www.drstockpick.com/disclaimer

Pretium Res Inc (PVG) Stock Research Links

PVG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading